Friday, August 11, 2023
Antengene and Hansoh Pharma have entered into collaboration agreement aimed at the commercialisation of XPOVIO®, a First and Only-in-class XPO1 inhibitor, in mainland China.
The collaboration agreement outlines distinct roles for both companies. Antengene will retain responsibilities for research and development, regulatory approvals and affairs, as well as product supply and distribution of XPOVIO®, while Hansoh Pharma will exclusively oversee the commercialisation aspects of the drug within mainland China.
Under the terms of agreement, Antengene is set to receive upfront payments totalling up to RMB 200 million. Of this amount, RMB 100 million will be provided upon the signing of the agreement, and the remaining upfront payments, subject to the stipulations outlined in the Agreement, could reach up to RMB 100 million. Additionally, Antengene stands to gain milestone payments from Hansoh Pharma, potentially reaching up to RMB 535 million.
XPOVIO® itself is positioned as a drug with significant commercial promise, particularly in addressing the pressing and unmet medical needs of patients with haematologic conditions in China. Beyond its existing approvals in multiple countries and regions for addressing conditions such as multiple myeloma and diffuse large B-cell lymphoma, XPOVIO® holds potential for further indication expansion.